BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 17, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/14 cls
Celldex Therapeutics Inc. (NASDAQ:CLDX) Needham Mark Monane Price target Buy 20% $9.01
Monane raised his target to $12 from $8 ahead of data for the company's pipeline to be presented at the American Society for Clinical Oncology meeting in Chicago. He believes the full potential of Celldex's lead product, CDX-110 (PF-04948568), and other pipeline candidates is "not fully appreciated." The vaccine targeting EGFR variant III (EGFRvIII) is in Phase II testing to treat glioblastoma multiforme and is partnered with Pfizer Inc. (NYSE:PFE).
Dynavax Technologies Corp. (NASDAQ:DVAX) ...

Read the full 660 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >